Introduction
============

Severe acute respiratory syndrome coronavirus-2 (SARS-COV-2), the cause of coronavirus disease-19 (COVID-19),[@b1-dic-2020-5-7] was first reported to the World Health Organization (WHO) on December 31, 2019,[@b2-dic-2020-5-7] and declared a global pandemic on March 11, 2020.[@b3-dic-2020-5-7] To date, there are approximately 5.8 million confirmed cases and over 350,000 deaths globally.[@b4-dic-2020-5-7] There are no Food and Drug Administration[@b5-dic-2020-5-7] or European Medicines Agency[@b6-dic-2020-5-7] approved vaccines or medications for the treatment of COVID-19. No specific therapies are recommended by the Centers for Disease Control and Prevention,[@b7-dic-2020-5-7] Infectious Diseases Society of America,[@b8-dic-2020-5-7] Society for Critical Care Medicine,[@b9-dic-2020-5-7] or WHO[@b10-dic-2020-5-7] outside of clinical trials. The National Institutes of Health (NIH)[@b11-dic-2020-5-7] guideline was recently updated to recommend remdesivir in certain patients based on preliminary evidence from clinical trials.

Despite absence of guideline-supported recommendations, several therapies thought to be effective for COVID-19 are in use around the world. However, access to these treatments is not equitable among all populations.[@b12-dic-2020-5-7] Remdesivir and chloroquine/hydroxychloroquine are drug therapies that have received the most attention.

Remdesivir was initially available through individual compassionate use requests. This pathway was halted for the majority of patients due to the overwhelming numbers of requests and the need to focus on clinical trials. Remdesivir access was then limited to these clinical trials and expanded access programs.[@b13-dic-2020-5-7] However, not all patients had the equal opportunity to enroll due to study site locations and eligibility criteria.[@b14-dic-2020-5-7],[@b15-dic-2020-5-7] It was only on May 1, 2020, that the FDA granted emergency use authorization (EUA) for remdesivir. It is now available for suspected or confirmed disease in hospitalized adults and children with severe disease, which is defined as low blood oxygen levels or needing oxygen therapy or mechanical ventilation.[@b16-dic-2020-5-7] However, allocation of remdesivir through EUA has not been transparent, and fears grow as healthcare providers are faced with rationing the limited drug supply.[@b17-dic-2020-5-7],[@b18-dic-2020-5-7]

Chloroquine and its metabolite hydroxychloroquine are widely prescribed for other indications. However, when reports emerged of their possible activity against SARS-COV-2, shortages quickly developed in the United States (US).[@b19-dic-2020-5-7]--[@b21-dic-2020-5-7] These drugs can be obtained for COVID-19 treatment through the FDA EUA, but use is reserved for only the sickest patients in certain hospitals.[@b22-dic-2020-5-7] Additionally, chloroquine and hydroxychloroquine are associated with potentially severe cardiac side effects.[@b23-dic-2020-5-7] Furthermore, an early clinical trial failed to demonstrate efficacy.[@b24-dic-2020-5-7]

Another potential therapy showing promise is the 14-day combination of lopinavir, 400 mg, and ritonavir, 100 mg orally every 12 h, ribavirin, 400 mg orally every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days when compared to 14 days of lopinavir, 400 mg, and ritonavir, 100 mg, every 12 h. This multicenter, prospective, open-label, randomized, phase 2 trial conducted at six sites in Hong Kong demonstrated that the triple antiviral therapy was safe and superior to lopinavir and ritonavir alone.[@b25-dic-2020-5-7]

Due to concerns over equitable access and adverse events of notable experimental treatments, we aimed to investigate potential alternative agents for treatment of COVID-19 that may have better availability and side effect profiles. Vitamins and essential nutrients are well known for their overall tolerability and requisite role in immune function. Thus, they were a natural choice for our investigation. This narrative review summarizes current and ongoing clinical trials of high-dose vitamins and supplements, alone or in combination with each other or other therapies, for the treatment of COVID-19. While not the focus of this review, vitamins and supplements may have an additional benefit in COVID-19 prevention, with a number of clinical trials planned to investigate this hypothesis. If shown to be safe and effective, vitamins and supplements may provide the much-needed answer to the COVID-19 pandemic.

Methods
=======

The authors searched the NIH US Library of Medicine Clinical Trials Database ([www.clinicaltrials.gov](www.clinicaltrials.gov)) and the WHO's International Clinical Trials Registry Platform (WHO ICTRP) via the NIH (<https://clinicaltrials.gov/ct2/who_table>). Prospective interventional trials of vitamins and/or supplements, excluding Chinese traditional medicine (CTM), for the treatment of COVID-19 posted on or before May 4, 2020, were included. Synonyms for COVID-19 were SARS-COV-2, 2019-nCOV, 2019 novel coronavirus, and SARS-COV-2. Additional search terms of 'vitamin' and 'supplement' were used to narrow search results. Traditionally, indexed literature and abstracts would have been added to the search methodology, but given the novelty of the subject, Medline and Embase searches for interventional studies yielded no results. This manuscript was exempted from ethics review as it did not involve human subjects.

Results
=======

In the NIH COVID-19 database, the additional search terms of 'vitamin' yielded 28 studies and 'supplement' yielded 115 additional studies. Of these 143 studies, 18 met inclusion criteria from this database ([Figure 1](#f1-dic-2020-5-7){ref-type="fig"}). Reasons for study exclusion were: erroneous search result (n=103); vitamin/supplement given as placebo, control, or standard of care (n=9), CTM (n=4); prevention study (n=5); diet plan as intervention (n=2; Ayurveda and ketogenic); and methodology (n=2; retrospective design and COVID-19 not required for inclusion).

Filtering the NIH's WHO ICTRP COVID-19 study table using the terms 'vitamin' yielded 27 studies. Filtering by 'supplement' yielded 36 additional studies. Of those 63 studies, 12 met inclusion criteria from this database. Reasons for study exclusion were: erroneous search result (n=37), diagnostic study (n=3), cancelled by investigator (n=3), CTM (n=2), prevention study (n=4), retrospective design (n=1), and vitamin/supplement given as placebo, control, or standard of care (n=1). One trial was dual registered in the American and European databases, leaving 11 unique studies.

Of the two clinical trial registries searched, a total of 29 studies met inclusion for evaluation and focused on the role of fatty acids, honey, medicinal plant extracts, probiotics, vitamins A, B, C, and D, and zinc ([Table 1](#t1-dic-2020-5-7){ref-type="table"}). Although these studies are ongoing and enrolling subjects, it is important to understand the potential role of these supplements and vitamins ([Table 2](#t2-dic-2020-5-7){ref-type="table"}).

The vitamins and supplements are under investigation in these trials largely as a result of their anti-inflammatory and antioxidant properties.[@b26-dic-2020-5-7]--[@b54-dic-2020-5-7] It is postulated that honey also has antiviral properties.[@b34-dic-2020-5-7],[@b35-dic-2020-5-7] [Table 1](#t1-dic-2020-5-7){ref-type="table"} highlights the mechanism of action, commercial availability, common uses, considerations for adverse events and drug--drug interactions, and proposed use in COVID-19 for the vitamins and supplements.

Twelve studies in six countries seek to evaluate nutritional supplementation or supplements for the treatment of COVID-19.[@b55-dic-2020-5-7]--[@b66-dic-2020-5-7] Agents evaluated in these studies are α-lipoic acid (ALA) (n=2),[@b55-dic-2020-5-7],[@b56-dic-2020-5-7] curcumin (n=1),[@b57-dic-2020-5-7] *Chlorella vulgaris* (green algae) with a herbal tea blend (n=1),[@b58-dic-2020-5-7] escin (n=1),[@b59-dic-2020-5-7] honey (n=1),[@b60-dic-2020-5-7] Imfluna (=1),[@b61-dic-2020-5-7] n-acetyl cysteine (NAC) (n=2)[@b62-dic-2020-5-7],[@b63-dic-2020-5-7], fatty-acid/antioxidant-enriched oral supplement (n=1),[@b64-dic-2020-5-7] probiotics (n=1),[@b65-dic-2020-5-7] and resistant starch (n=1).[@b66-dic-2020-5-7] Nineteen studies in eight countries seek to evaluate vitamins and minerals for the treatment of COVID-19.[@b67-dic-2020-5-7]--[@b83-dic-2020-5-7] Agents evaluated in these studies are: vitamin A (n=3),[@b67-dic-2020-5-7]--[@b69-dic-2020-5-7] vitamin B (n=2),[@b69-dic-2020-5-7],[@b70-dic-2020-5-7] vitamin C (n=10),[@b69-dic-2020-5-7],[@b71-dic-2020-5-7]--[@b78-dic-2020-5-7] vitamin D (n=8),[@b64-dic-2020-5-7],[@b69-dic-2020-5-7],[@b77-dic-2020-5-7],[@b79-dic-2020-5-7]--[@b83-dic-2020-5-7] and zinc (n=3).[@b77-dic-2020-5-7],[@b78-dic-2020-5-7] The sum of studies here is more than 29, as multiple agents are investigated in some trials. For each study, [Table 2](#t2-dic-2020-5-7){ref-type="table"} provides the trial location, design, treatment arms, requirements for treatment, status, planned end date, and endpoints.

The majority of vitamin supplements in these trials are administered orally, although some are parenteral. ALA is administered parenterally in both studies,[@b55-dic-2020-5-7],[@b56-dic-2020-5-7] escin is administered parenterally in one arm of its study,[@b59-dic-2020-5-7] NAC[@b62-dic-2020-5-7] and vitamin B[@b69-dic-2020-5-7] are administered parenterally in one study each, and vitamin C is administered parentally[@b71-dic-2020-5-7]--[@b78-dic-2020-5-7] in all studies except one.[@b69-dic-2020-5-7] Intervention and comparator arms vary across the trials.[@b55-dic-2020-5-7]--[@b83-dic-2020-5-7] The intervention arms call for the study agent to be given alone, in combination with other study agents, or with standard of care. Comparator arms include other study agents (e.g. adalimumab), standard of care, and/or placebo. Standard of care is not described in all trails. It may only be defined as such or specific antivirals (e.g. hydroxychloroquine and azithromycin) may be listed. Study agents investigated in combination in at least one arm of one study are: methylene blue plus vitamin C plus NAC,[@b62-dic-2020-5-7] vitamin D plus NAC,[@b63-dic-2020-5-7] and oxygen--ozone therapy plus probiotics,[@b65-dic-2020-5-7] vitamins A, B, C, D, plus E,[@b69-dic-2020-5-7] quintuple therapy of vitamins C and D plus zinc plus hydroxychloroquine and azithromycin,[@b77-dic-2020-5-7] vitamin C plus zinc,[@b78-dic-2020-5-7] vitamin D plus aspirin,[@b81-dic-2020-5-7] and vitamin D plus zinc[@b83-dic-2020-5-7] (n=1 for all).

There are a wide range of planned primary and secondary outcomes among the studies.[@b55-dic-2020-5-7]--[@b83-dic-2020-5-7] Notable planned outcomes include disease progression or recovery, adverse events, mortality, change in symptoms, vitals, radiology, and/or laboratory inflammatory markers, and rate of, length of, or time to hospitalization or mechanical ventilation. The study expected to have peer-reviewed results earliest is of ALA plus standard of care in critically ill patients with COVID-19.[@b56-dic-2020-5-7] The majority of the other trials are recruiting (n=15). This is followed by not yet recruiting (n=11), enrolling (n=1), and recruitment compete (n=1).[@b55-dic-2020-5-7],[@b57-dic-2020-5-7]--[@b83-dic-2020-5-7]

Discussion
==========

Although the full potential of vitamins and herbal supplements have not been elucidated, various studies are underway to assess these agents as potential treatment options and/or additive therapies to current treatment choices that vary around the world as there is no definitive treatment at this point in time. Depending on the formulation, vitamins and herbal supplements are relatively affordable and accessible. Availability in certain markets may be limited as this novel virus has caused patients and providers to stockpile medications, vitamins, and supplements for later use without proven efficacy and unknown safety profiles at higher than normal doses, leading to imposing limitations on the quantity that can be purchased.[@b84-dic-2020-5-7]

Although the use of remdesivir has been expanded in the United States, its role in the fight of COVID-19 has not provided patients and providers with the relief they expected. Although no difference in clinical outcomes was observed between 5 and 10 days of remdesivir treatment, a study conducted in Hubei, China, failed to demonstrate clinical improvements in adults with severe COVID-19 in the remdesivir arm.[@b85-dic-2020-5-7],[@b86-dic-2020-5-7] Interestingly, time to clinical improvement in patients treated earlier was observed but needs confirmation in larger studies.[@b85-dic-2020-5-7] In an exploratory analysis, the sponsor of remdesivir, Gilead Sciences, Inc., found that patients who received remdesivir within 10 days of symptoms onset had improved outcomes compared with those treated after more than 10 days of symptoms. Additionally, when data were pooled across treatment arms, by Day 14, 62% of patients treated early were discharged from the hospital compared to those who were treated late; yet statistical analysis was not performed.[@b86-dic-2020-5-7] Furthermore, notable exclusion criteria in these moderate-to-severe COVID-19 patients included mechanical ventilation at screening as well as patients receiving mechanical ventilation \> 5 days or extracorporeal membrane oxygenation, alanine aminotransferase or aspartate aminotransferase \> 5 X upper limit of normal (ULN), and creatinine clearance (CrCL) \< 50 mL/min.[@b14-dic-2020-5-7],[@b15-dic-2020-5-7] Therefore, the true potential and efficacy of remdesivir therapy require expanded investigation into additional populations.

Although doses of vitamins in these ongoing clinical trials are higher than normal, use of vitamins at higher doses compared to recommended dietary allowance is safe, and upper limits for the use are defined. In addition, the use of vitamins and herbal supplements likely has more benign side effects when compared to self-medicating with unproven remedies lacking adequate investigations for use. In the instance of chloroquine phosphate and its derivative hydroxychloroquine, a wife and husband ingested chloroquine phosphate in the United States in March 2020, after hearing from a press conference that this medication was likely a very promising treatment option. The couple consumed hydroxychloroquine based on the intended use for their aquarium because they feared contracting the virus, and it was easily accessible. They were both hospitalized shorty after ingesting the product, and the husband ultimately died.[@b87-dic-2020-5-7] Meanwhile, hundreds in Iran died after drinking neat alcohol in early 2020, which was publicized on social media as a cure/prevention for COVID.[@b88-dic-2020-5-7] It is not clear how many of these deaths can be directly tied to social media misinformation, as a larger problem of contaminated bootleg alcohol was revealed.

The most studied supplement in the acute care setting has been vitamin C, where it has been used as treatment for multiple conditions, including sepsis, acute bronchitis, cardiovascular disease, postoperative infection, and prevention of contrast-induced nephropathy. A meta-analysis published in 2019, reviewed 18 trials to evaluate the effect of vitamin C on intensive care unit (ICU) length of stay and duration of mechanical ventilation. The most commonly studied populations were patients undergoing cardiac surgery, followed by sepsis, lung contusions, and burn patients. Of 12 trials containing 1766 patients, intravenously administered vitamin C reduced the length of ICU stay by 7.8% (95% confidence interval \[CI\]: 4.2--11.2; *p*=0.00003). Orally administered vitamin C in doses of 1--3 g/day was evaluated in 6 studies and was associated with reduced length of ICU stay by 8.6% (*p*=0.003). Of the 3 studies evaluating patients requiring mechanical ventilation for \>24 h, vitamin C reduced the duration of mechanical ventilation by 18.2% (95% CI: 7.7--27; *p*=0.001).[@b89-dic-2020-5-7]

These authors also performed a meta-regression analysis in critically ill patients receiving mechanical ventilation and found that in 5 studies consisting of 471 patients, vitamin C (1--6 g/day) was most beneficial in reducing ventilation time by an average of 25% (*p*\<0.0001) in patients requiring more than 10 h of mechanical ventilation.[@b90-dic-2020-5-7] These findings can serve as a foundation for analyzing the role of vitamin C in potentially reducing the time spent on mechanical ventilation in patients with COVID-19.

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS-ALI), a randomized, double-blind, placebo-controlled, multicenter trial conducted in 7 medical ICUs in the USA evaluated the effects of vitamin C infusion in 167 patients and its role in organ failure along with biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure. Patients were assigned to receive either an infusion of vitamin C, 50 mg/kg, or placebo dextrose, 5% in water, every 6 h for 96 h. Although this study failed to improve organ dysfunction scores or alter markers of inflammation and vascular injury, vitamin C was associated with a significant reduction in 28-day all-cause mortality as well as significantly increased ICU-free days to day 28 and hospital-free days to day 60.[@b91-dic-2020-5-7] These findings also suggest that further research may be warranted to determine whether vitamin C has a role in the care of patients with sepsis and acute respiratory distress syndrome (ARDS), which has been associated with COVID-19.

Vitamin D is currently under evaluation for its role in COVID-19 for its immunomodulatory effects. A trial conducted in Guinea-Bissau investigated vitamin D as supplementary treatment for tuberculosis in 365 patients. The intervention was 100,000 IU of cholecalciferol or placebo at inclusion and again at 5 and 8 months after the initiation of treatment. Findings from this study failed to demonstrate improvements in clinical outcomes or mortality in patients receiving vitamin D as part of tuberculosis treatment, but this may be due to the dose not being high enough or given consistently.

Additional studies evaluating the role of vitamin D supplementation in the prevention and reduction of acute respiratory infections, COPD exacerbations, and pneumonia were analyzed in the Vitamin D3 Supplementation in Patients with Chronic Obstructive Pulmonary Disease (ViDiCO) trial. This trial investigated whether vitamin D3 supplementation would reduce the incidence of moderate or severe COPD exacerbations and upper respiratory infections in 240 patients across clinics in London. Patients received six 2-month oral doses of 3 mg of vitamin D over a 1-year period. Vitamin D3 was associated with protective effects against moderate or severe COPD exacerbations in participants with baseline serum 25-hydroxyvitamin D concentrations of less \<50 nmol/L (*p*=0·021), but not in those with baseline concentrations \> 50 nmol/L. Baseline serum 25-hydroxyvitamin D concentrations had no effect on time to first upper respiratory infection.[@b92-dic-2020-5-7]

A systematic review and meta-analysis evaluated 24 randomized, controlled trials of supplementation with vitamin D in regard to incidence of acute respiratory tract infection. Protective effects were observed in subjects receiving daily or weekly vitamin D supplementation without additional bolus doses and were stronger in those with baseline 25-hydroxyvitamin D levels \<25 nmol/L. Serum 25(OH)D concentration was inversely associated with risk and severity of acute respiratory tract infection; where for each 10 nmol/L decrease in 25(OH)D concentration, the odds of acute respiratory tract infection increased by 1.02 (0.97--1.07).[@b93-dic-2020-5-7] Therefore, some protective effects of vitamin D in those with lower baseline levels have been seen. However, the role of vitamin D for the treatment of acquired infections, including COVID-19, requires further investigation especially in subjects with low baseline levels of vitamin D. This concept is currently under investigation in France.[@b94-dic-2020-5-7]

When evaluating proposed studies of vitamins and supplements throughout the world, there are notable limitations in currently available information, such as standard of care. While many of the studies report a comparator arm as standard of care, there is no definition of what that actually means as there is no widely recognized treatment for COVID-19. In addition, much like other clinical trials, key populations are excluded in many of these ongoing trials as well. This includes women, who are pregnant or lactating, as well as patients with chronic diseases (i.e. kidney disease), or patients with short life expectancies (i.e. cancers).

The greatest promise in combatting this life-threatening virus appears to be through reducing the cytokine storm associated with COVID-19.[@b95-dic-2020-5-7] This is where anti-inflammatory and antioxidant vitamins and supplements may play a potential role. Results of these ongoing clinical trials are urgently needed.

At this time, we recommend vitamins and supplements as specific COVID-19 treatment in the context of a clinical trial. This recommendation is in-line with the major organizational guidelines for potentially effective COVID-19 treatments at the time of this writing. While the vitamins and supplements under investigation for COVID-19 described in this manuscript are generally without serious adverse effects and drug interactions, no therapy is completely free of risk. Additionally, while also being generally affordable, broad recommendation and implementation of unproven treatments are likely not cost effective. That being said, vitamins and supplements with existing evidence supporting their use in conditions associated with COVID-19, such as sepsis or ARDS, can be considered when potential benefit is determined to outweigh risk.

Conclusion
==========

With the rapidity of hypothetical treatments' data being generated for COVID-19, clinical investigations up until this point have not provided efficacious treatments in eradicating the virus. While it is important to investigate treatments with the potential to reduce the severity and consequences of COVID-19, vitamins and supplements should be continued to be evaluated to provide the much-needed evidence for possible treatment modalities. A systematic review will be conducted once results from ongoing and recruiting clinical trials are available.
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###### 

Characteristics of vitamins and supplements under investigation for SARS-CoV-2.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                                                                                            MOA                                                                                                                                                    Commercial product    Most common use(s)                                                                                                                                                          Considerations and usual dose                                                                                                              Proposed use in COVID-19[@b55-dic-2020-5-7]--[@b83-dic-2020-5-7]
  ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Nutritional supplementation or supplements***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Alpha-lipoic acid[@b26-dic-2020-5-7],[@b27-dic-2020-5-7]                                        Antioxidant                                                                                                                                            Yes                   --Aging skin--Cognitive impairment/dementia--Diabetes--Diabetic neuropathy--Dyslipidemia--Multiple sclerosis--Weight loss                                                   AE: allergic reaction, hypoglycemia, changes in vision\                                                                                    Antioxidant effects\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: chemotherapy, antidiabetics\                                                                                                          Dosing: 1200 mg/d IV
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Usual daily dose: 150--1800 mg                                                                                                             

  Curcumin[@b28-dic-2020-5-7],[@b29-dic-2020-5-7]                                                 Antioxidant, anti-inflammatory; active polyphenol of *Curcuma longa* (turmeric)                                                                        Yes                   --Inflammatory conditions                                                                                                                                                   AE: GI complaints\                                                                                                                         Symptom improvement\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no major; caution with: alkylating agents, anticoagulants, antiplatelets, antidiabetics\                                              Specific product under investigation: SinaCurcumin\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Usual daily dose: 180 mg--2.5 g                                                                                                            Dosing: 40 mg PO BID × 2 wks, then daily

  *Chlorella vulgaris* (Freshwater green algae)[@b30-dic-2020-5-7],[@b31-dic-2020-5-7]            Nutrient and antioxidant                                                                                                                               Yes                   --Cancer--Liver disease--Infections--Skin ulcerations--Toxicity (lead, mercury)--Aging                                                                                      AE: GI complaints, fatigue, photosensitivity, thrombocytopenia\                                                                            Symptom improvement\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: warfarin (high in vitamin K)\                                                                                                         Dosing: 300 mg PO QID with herbal tea blend
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Usual daily dose: 600 mg--2 g                                                                                                              

  Escin[@b32-dic-2020-5-7],[@b33-dic-2020-5-7]                                                    Anti-inflammatory and vasoconstrictor; triterpene saponin (active compound) in *Aesculus hippocastanum* (horse chestnut); part of plant dictates use   Yes                   --CVI--Other venous conditions--IBS--Malaria--Eczema--Skin ulcers                                                                                                           AE: dizziness, GI complaints, headache, pruritus, calf spasms; bark can be nephrotoxic\                                                    Reduce cytokine-mediated lung damage\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no major; caution with anticoagulants, antiplatelets, antidiabetics\                                                                  Dosing: 40 mg PO TID
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Usual daily dose, CVI: 100--150 mg                                                                                                         

  Natural honey[@b34-dic-2020-5-7],[@b35-dic-2020-5-7],[@b96-dic-2020-5-7]                        Antiviral, antitussive, and antimicrobial (due to high osmolarity and concentration of H2O2)                                                           Yes                   --Antimicrobial agent (antibacterial, antifungal, antiviral, antimycobacterial)--Cough caused by URI--Topical wound treatment[a](#tfn1-dic-2020-5-7){ref-type="table-fn"}   AE: abdominal pain, nausea, vomiting, hyperglycemia with large doses, botulism (do not use in children \< 1 yo)\                           Possible antiviral effects and acute cough\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: none\                                                                                                                                 Dosing: 1 gram/kg/day split into 2--3 doses
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DRI, added sugars: ≤25% of total energy                                                                                                    

  Imfluna[@b36-dic-2020-5-7]                                                                      Not reported                                                                                                                                           Not available in US   Not reported                                                                                                                                                                NR                                                                                                                                         Mixture of medicinal plant extract powder manufactured by HomaPharmed Pharmaceutical Company; proposed MOA not reported\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Dosing: 500 mg capsule × 3 PO TID AC

  N-acetyl cystine (NAC)[@b37-dic-2020-5-7],[@b38-dic-2020-5-7]                                   Antioxidant                                                                                                                                            Yes                   --APAP poisoning[a](#tfn1-dic-2020-5-7){ref-type="table-fn"}--Lung diseases[a](#tfn1-dic-2020-5-7){ref-type="table-fn"}--Contrast-induced nephropathy prevention            AE: GI complaints (\> with PO), CNS effects; IV: rash, hypersensitivity\                                                                   Antioxidant effects by supporting the synthesis of glutathione\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: nitroglycerine (major), use caution: ACE-I, anticoagulants, antiplatelets, chloroquine[b](#tfn2-dic-2020-5-7){ref-type="table-fn"}\   Dose: 600 mg PO daily; dose not provided IV
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Lab: decreased PT\                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Usual dose, APAP poisoning: 1220 mg/kg PO over 72 h or 200 mg/kg IV over 21 h                                                              

  Oral nutritional supplements (ONS)[@b39-dic-2020-5-7],[@b40-dic-2020-5-7],[@b96-dic-2020-5-7]   Anti-inflammatory and antioxidant                                                                                                                      Yes                   --Nutrition--Weight gain                                                                                                                                                    AE: diarrhea, nausea, bloating, exhaustion, increased pulse\                                                                               May reduce the severity of COVID-19 by preserving nutritional status\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: fluoroquinolones\                                                                                                                     High doses of n3-fatty acids and antioxidant vitamins may act as an anti-inflammatory agent to modulate cytokine production and reduce damage to the lungs from the associated cytokine storm\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           RDA:\                                                                                                                                      Specific product under investigation: Oxepa (Abbott Nutrition, Abbott Laboratories); 14.8 g protein, 22.2 g fat, 25 g carbohydrate, 355 kcal, 1.1 g EPA, 450 mg DHA, 950 mg GLA, 2840 IU vitamin A as 1.2 mg β-carotene, 205 mg Vitamin C, 75 IU vitamin E, 18 ug Selenium, and 5.7 mg Zinc\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Protein: 56 g (M), 46 g (F)\                                                                                                               \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Fat: ND\                                                                                                                                   Dose: 8 oz PO every AM separated from meals
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Carbohydrate: 130 g (M or F)\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Fatty acids (AI): 1.6 g (M), 1.1 g (F)\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Selenium: 55 μg (M or F)\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Also see other table entries\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL:\                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Protein: NR\                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Fat: NR\                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Carbohydrate: NR\                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Fatty acids: 3 g (M or F)\                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Selenium: 400 μg (M or F)\                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Also see other table entries                                                                                                               

  Probiotics[@b41-dic-2020-5-7],[@b42-dic-2020-5-7]                                               Interfere with pathogenic bacteria growth (competition), improve barrier function of epithelium, and immunomodulation                                  Yes                   --GI disorders--Mood disorders                                                                                                                                              AE: GI upset, infection\                                                                                                                   Restore microbial flora\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no concerns\                                                                                                                          Specific product under investigation: Sivomixx (Streptococcus *thermophilus* DSM 322245, *Bifidobacterium lactis* DSM 32246, *Bifidobacterium lactis* DSM 32247, *Lactobacillus acidophilus* DSM 32241, *Lactobacillus helveticus* DSM 32242, *Lactobacillus paracasei* DSM 32243, *Lactobacillus plantarum* DSM 32244, *Lactobacillus brevis* DSM 27961)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Usual daily dose, Sivomixx: 1--2 sachets                                                                                                   Dose: 6 sachets PO BID

  Resistant starch[@b43-dic-2020-5-7],[@b44-dic-2020-5-7],[@b96-dic-2020-5-7]                     Increase butyrate production in the colon; type determines specific properties                                                                         Yes                   --Improve gut health/microbiota--Improve serum inflammatory biomarkers                                                                                                      AE: flatulence\                                                                                                                            Anti-inflammatory effects\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no concerns\                                                                                                                          Dose: 2 tbsp (\~20 g) PO daily × 3 d, then BID
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           AI, fiber: 38 g (M or F)\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL: NR                                                                                                                                     

  ***Vitamins & minerals***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Vitamin A[@b45-dic-2020-5-7],[@b46-dic-2020-5-7],[@b96-dic-2020-5-7]                            Essential fat-soluble micronutrient                                                                                                                    Yes                   --Deficiency--Vision conditions--Infection--Wound healing                                                                                                                   AE: hypervitaminosis with high doses, chronic use\                                                                                         Supplementation for reduced levels during infection\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no concerns at usual doses\                                                                                                           Dose: 25,000--50,000 IU PO daily
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           RDA: 900 μg (M), 700 (F) μg[c](#tfn3-dic-2020-5-7){ref-type="table-fn"}\                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL: 3000 μg (M or F)[c](#tfn3-dic-2020-5-7){ref-type="table-fn"}                                                                           

  Vitamin B[@b47-dic-2020-5-7],[@b48-dic-2020-5-7],[@b96-dic-2020-5-7]                            Essential water-soluble vitamin; each has own specific properties                                                                                      Yes                   --Deficiency--Mood disorders--Energy--Cell growth                                                                                                                           AE: no major\                                                                                                                              Anti-inflammatory effects\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no concerns\                                                                                                                          Specific products under investigation:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           RDA:\                                                                                                                                      Nicotinamide (vitamin B3)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Thiamin: 1.2 mg (M), 1.1 mg (F)\                                                                                                           \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Riboflavin: 1.3 mg (M), 1.1 mg (F)\                                                                                                        Dose: 1000 mg PO daily\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Niacin: 16 mg (M), 14 mg (F)\                                                                                                              \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Pyridoxine: 1.3 mg (M or F)\                                                                                                               Soluvit (thiamine 3.1 mg, riboflavin 4.9 mg, nicotinamide 40 mg, pyridoxine 4.9 mg, pantothenate 16.5 mg, ascorbate 113 mg, biotin 60 mcg, folic acid 400 mcg, cyanocobalamin 5 mcg)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Pantothenate (AI): 5 mg (M or F)\                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Biotin (AI): 30 μg (M or F)\                                                                                                               Dose: 1 ampule PO daily
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Folic acid: 400 μg (M or F)\                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL:\                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Thiamin: ND\                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Riboflavin: ND\                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Niacin: 35 mg (M or F)\                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Pyridoxine: 100 mg (M or F)\                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Pantothenate: ND\                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Biotin: ND\                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Folic acid: 1000 μg (M or F)                                                                                                               

  Vitamin C (ascorbic acid)[@b49-dic-2020-5-7],[@b50-dic-2020-5-7],[@b96-dic-2020-5-7]            Antioxidant and enzymatic cofactor                                                                                                                     Yes                   --Deficiency/nutrition[a](#tfn1-dic-2020-5-7){ref-type="table-fn"}--Cancer prevention[d](#tfn4-dic-2020-5-7){ref-type="table-fn"}--URI--Aging skin--Sepsis--Wound healing   AE: osmotic diarrhea, GI upset (high PO doses), hemolytic anemia if G6PD deficient\                                                        Stimulates IFN production, which supplies lymphocyte proliferation and enhances neutrophil phagocytic capability\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no major; use caution: estrogens, antihyperlipidemics\                                                                                Dose: wide range, given either IV and PO ([Table 2](#t2-dic-2020-5-7){ref-type="table"})
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           Lab: false BG elevation\                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           RDA: 90 mg (M), 75 mg (F)\                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL: 2000 mg (M or F)                                                                                                                       

  Vitamin D (calciferol)[@b50-dic-2020-5-7],[@b51-dic-2020-5-7],[@b96-dic-2020-5-7]               Essential fat-soluble vitamin                                                                                                                          Yes                   --Deficiency--Hypoparathyroidism--Osteomalacia--Osteoporosis--Osteoporosis prevention[d](#tfn4-dic-2020-5-7){ref-type="table-fn"}--Psoriasis                                AE: intoxication with excessive doses\                                                                                                     Immunomodulatory and induces secretion of antimicrobial peptides\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no major; use caution: CYP P450 3A4 substrates\                                                                                       Dose: 25,000--400,000 IU PO daily
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           RDA: 15 μg (M or F)[e](#tfn5-dic-2020-5-7){ref-type="table-fn"}\                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL: 100 μg (M or F)[e](#tfn5-dic-2020-5-7){ref-type="table-fn"}                                                                            

  Vitamin E (tocopherol)[@b52-dic-2020-5-7],[@b53-dic-2020-5-7],[@b96-dic-2020-5-7]               Fat-soluble vitamin                                                                                                                                    Yes                   --Deficiency--CVD--Diabetes--Diabetic complications--Cancer prevention--Infections                                                                                          AE: GI upset, headache, blurred vision\                                                                                                    Antioxidant and immunomodulatory effects\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no major; use caution: alkylating agents, anticoagulants, antiplatelets, CYP P450 3A4 substrates, warfarin\                           Dose: 300 IU PO daily
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           RDA: 15 mg (M or F)[f](#tfn6-dic-2020-5-7){ref-type="table-fn"}\                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL: 1000 mg (M or F)[f](#tfn6-dic-2020-5-7){ref-type="table-fn"}                                                                           

  Zinc[@b50-dic-2020-5-7],[@b54-dic-2020-5-7],[@b96-dic-2020-5-7]                                 Essential mineral                                                                                                                                      Yes                   --Deficiency--AMD--Infections--Wound healing                                                                                                                                AE: GI upset, metallic taste\                                                                                                              Antiviral properties and essential for immune function\
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          \
                                                                                                                                                                                                                                                                                                                                                                                                                                                           DDI: no major; use caution: antidiabetics, drugs susceptible to chelation in the gut\                                                      Dose: 15--30 mg PO daily
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           RDA: 11 mg (M), 8 mg (F)\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           UL: 40 mg (M or F)                                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FDA approved indication;

Decreased effect; special caution as this is a proposed CoVID-19 treatment;

1 IU = 0.15 μg as RAEs for β-carotene supplement[@b97-dic-2020-5-7];

FDA approved qualified health claim;

1 IU = 0.025 μg[@b97-dic-2020-5-7];

1 IU = 0.69 μg for natural and 0.45 μg for synthetic[@b97-dic-2020-5-7].

AC, after meals; AE, adverse event; AI, adequate intake (used when insufficient evidence to calculate RDA); AMD, age-related macular degeneration; BG, blood glucose; BID, twice daily; CNS, central nervous system; CVD, chronic vascular disease; CVI, chronic venous insufficiency; CYP, cytochrome; d, days; DDI, drug-drug interaction; DRI, dietary reference intake; F, female; FDA, US Food and Drug Administration; GI, gastrointestinal; GLA, gamma-linolenic acid; H2O2, hydrogen peroxide; hrs, hours; HSV-1, herpes simplex virus 1; IBS, irritable bowel syndrome; IM, intramuscular; IV, intravenous; kg, kilogram; M, male; MOA, mechanism of action; ND, not determinable; NICE, National Institute for Health and Care Excellence; NOS, nitric oxide synthase; NR, not reported; Oz, ounces; PHE, Public Health England; PO, oral; PT, prothrombin time; QID, four times daily; RAE, retinol activity equivalents; RDA, recommended dietary allowance (non-pregnant adults 19--50 yo); TID, three times daily; UL, tolerable upper intake level; URI, upper respiratory infection; US, United States; VZV, varicella zoster virus; wks, weeks; yo, years old.

###### 

Clinical trials of vitamins and supplements under investigation for SARS-CoV-2.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial ID and title                                                                                                                                                                                                                                                                                                                                         Location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Study design                                                                                                                                                                                                                       Treatment arms (n)                                                                                                                                                                                      Requirements for treatment (inclusion/exclusion)                                                                                                                                                                                                                                                                                                                                                  Status; study end date                  Planned endpoints (primary/secondary)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Nutritional supplementation or supplements and honey***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  ChiCTR2000030471[@b55-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                       China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Randomized, single-blind, multicenter                                                                                                                                                                                              α-Lipoic acid (ALA) injection, dose not provided (n=197)                                                                                                                                                Inclusion 18 to 75 yoMild patients with confirmed COVID-19                                                                                                                                                                                                                                                                                                                                        Recruiting; 4/30/20                     Primary Progression from mild to critical/severe
  Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Routine therapy (adalimumab) + placebo (n=197)                                                                                                                                                                                                                                                                                                             Exclusion Pregnancy or lactationAllergy or intolerance to study drugsEnrolled in other COVID-19 clinical trials Other foods or drugs with antioxidant effect (e.g. vitamin C, vitamin E)Other serious life-threatening diseases (e.g. cancer)                                                                                                                                                                                                                                                                                                  Secondary NEWS ScoreHospitalization30-d all-cause mortalityLevels of inflammatory factors and oxidative stress                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  ChiCTR2000029851[@b56-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                       China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Randomized, single-blind, single center                                                                                                                                                                                            SC + α-Lipoic acid 1200 mg/d IV × 7 d (n=8)                                                                                                                                                             Inclusion Critical illness of diagnosed COVID-19                                                                                                                                                                                                                                                                                                                                                  Completed; results pending              Primary SOFA score
  A randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  SC + placebo (equal volume saline infusion) × 7 d (n=9)                                                                                                                                                                                                                                                                                                    Exclusion Participation in other clinical trialsPregnant or breastfeedingLife-threatening diseases (e.g. cancer)Expected survival time \< 24 hAllergy or intolerance to study drugHistory of immune system or immune-related diseases                                                                                                                                                                                                                                                                                                          Secondary 30-d all-cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  IRCT20200408046990N1[@b57-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                   Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Non-randomized, open label, parallel group                                                                                                                                                                                         Sinacurcumin 40 mg 2 capsules PO BID × 2 wks then 1 capsule PO daily × 2 wks (n=30)                                                                                                                     Inclusion Mild-to-moderate COVID-19 by laboratory, radiologic, or clinical diagnosis18--65 yo                                                                                                                                                                                                                                                                                                     Not yet recruiting; 9/20/20             Primary Treatment response (fever, symptoms, radiologic)AEs
  Evaluation of SinaCurcumin as a complementary therapy in mild-to-moderate COVID-19: An open label non-randomized clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  SC (n=30)                                                                                                                                                                                                                                                                                                                                                  Exclusion \< 7 d from symptom startPregnancy or lactationAllergy to study drugConcomitant bacterial infectionSpO2 \< 90%\< 5 cigarettes/dSelected past medical diseases                                                                                                                                                                                                                                                                                                                                                                        Secondary LOS hospitalClinical outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  IRCT20151228025732N51[@b58-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                  Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Non-randomized, parallel control group, single center                                                                                                                                                                              SC + *C. vulgaris* 300 mg supplemented with herbal tea (2 g Pennyroyal; 2 g Chamomile, 1.4 g Hollyhocks, and 0.6 g Mallow) PO QID (n=30)                                                                Exclusion Malignant diseasesSevere renal, liver, and heart failureAnticoagulantsPregnancy or lactating                                                                                                                                                                                                                                                                                            Recruiting; 6/16/20                     Primary Clinical symptoms
  Effect of Algomed, *Menta longifolia*, Chamomile, *Althaea rosea*, *Malva sylvestris*, and *Lepidium sativum* supplements on the severity and consequences of coronavirus 19 disease (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  SC (n=30)                                                                                                                                                                                                                                                                                                                                                  Secondary None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  NCT04322344[@b59-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Italy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Non-randomized, double-blind, parallel assignment                                                                                                                                                                                  SC (antiviral therapy) + Escin tablet 40 mg PO TID × 12 d (n=40)                                                                                                                                        Inclusion 18--75 yoCOVID-19 positive screening test in molecular biologyIn escin group: low response to standard treatment                                                                                                                                                                                                                                                                        Recruiting; 6/30/20                     Primary All-cause mortalityClinical status
  Efficacy and safety of escin as add-on treatment in COVID-19 infected patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  SC (antiviral therapy) + sodium escinate 20 mg IV/d × 12 d (n=40)                                                                                                                                                                                                                                                                                          Exclusion Pregnant or breastfeedingAllergy/contraindication to escinAny condition inappropriate for study per investigatorsUnable to take oral medications                                                                                                                                                                                                                                                                                                                                                                                     Secondary Differences in O2 intake methodsLOS in hospital and/or ICUPulmonary function                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  SC (antiviral therapy) (n=40)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  NCT04323345[@b60-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Egypt                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Randomized, multicenter, controlled, phase 3                                                                                                                                                                                       Honey 1 g/kg/d PO or NGT divided into 2--3 doses × 14 d + SC (supportive measures and LPV/r, umifenovir, chloroquine, hydroxychloroquine, or oseltamivir w/or w/o azithromycin) (n=500)                 Inclusion Diagnosis of COVID-19 (clinically or confirmed by swab)5--75 yo                                                                                                                                                                                                                                                                                                                         Recruiting; 12/15/20                    Primary 14-d recovery from positive to negative swabs14-d fever recovery30-d lung CT or X-ray resolution
  The efficacy of natural honey in patients infected with novel coronavirus (COVID-19): A randomized, controlled, single masked, investigator initiated, multi-center trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  SC (see above) (n=500)                                                                                                                                                                                                                                                                                                                                     Exclusion Severely ill with terminal diseaseNPO patients with contraindication to NGT feeding                                                                                                                                                                                                                                                                                                                                                                                                                                                  Secondary 30-d mortalityTime to negative swab (30 d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  IRCT20080901001157N16[@b61-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                  Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Randomized, double-blind, phase 2, placebo-controlled, clinical trial                                                                                                                                                              500 mg capsules × 2 of herbal compound (mixture of medicinal plant extract powder manufactured by HomaPharmed Pharmaceutical Company) PO TID AC × 2 wks + SC (n=30)                                     Inclusion Symptomatic COVID-19 pneumonia confirmed with chest CT and PCR20--70 yoAble to take oral medication                                                                                                                                                                                                                                                                                     Recruiting; 6/14/20                     Primary SpO2Respiratory rateLung inflammation (CT scan)
  Evaluation of the effect of IMFLUNA herbal compound on the improvement of COVID-19 pneumonia symptoms in patients referred to Baqiyatallah Hospital                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  SC + placebo (n=30)                                                                                                                                                                                                                                                                                                                                        Exclusion Severe dyspnea or respiratory failure requiring mechanical ventilation or hospitalization in ICUsTreatment-resistant hypoxemia or those with severe underlying diseaseReduced level of consciousness or need of hospitalization in ICUsSwallowing disorders or possible aspirationUnable to take oral medicationsOrgan transplantationMalignant diseaseCorticosteroid or chemotherapy treatmentUncontrolled blood pressure, uncontrolled diabetes, cardiovascular disease and underlying respiratory diseasePregnant women           Secondary Laboratory inflammatory markersCough and fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  NCT04323228[@b64-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Saudi Arabia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Double-blind, prospective, single center, randomized controlled trial                                                                                                                                                              Oxepa (EPA, GLA, antioxidant ONS) 8 oz PO daily in AM separated from meals (n=15)                                                                                                                       Inclusion Confirmed SARS-CoV-2 infectionCOVID-19 patient in stable condition (i.e. not requiring ICU admission)18--65 yo                                                                                                                                                                                                                                                                          Not yet recruiting; 10/1/20             Primary Laboratory inflammatory and nutritional markers
  Anti-inflammatory/antioxidant oral nutrition supplementation in COVID-19 (ONSCOVID19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Isocaloric-isonitrogenous placebo (n=15)\                                                                                                                                                                                                                                                                                                                  Exclusion Tube feeding or PNPregnant or lactatingAdmission to ICU \> 24 hrsParticipation in another study including any supplementation or disease specific ONS                                                                                                                                                                                                                                                                                                                                                                                Secondary AnthropometricsTemperatureSpO2WBC counts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Same manufacturer, macronutrient composition, and calorie density, and normal concentrations of vitamin A, C, E, selenium and zinc                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  NCT04366089[@b65-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Italy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Interventional, open-label, randomized, parallel assignment                                                                                                                                                                        Oxygen-ozone therapy BID + SivoMixx (200 billion) probiotic supplementation, 6 sachets BID × 7 d + SC (azithromycin + hydroxychloroquine) (n=76)                                                        Inclusion \> 18 yoNasopharyngeal swab COVID-19 positiveCOVID-19 stages I-II-IIIHospitalized (non-ICU)                                                                                                                                                                                                                                                                                             Recruiting; 12/31/20                    Primary Intubation
  Oxygen--ozone as adjuvant treatment in early control of COVID-19 progression and modulation of the gut microbial flora (PROBIOZOVID)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  SC (azithromycin + hydroxychloroquine) (n=76)                                                                                                                                                                                                                                                                                                              Exclusion COVID-19 stages IV-V-VIICUPregnancyG6PD deficiencyContraindications to therapyHyper-homocysteinemiaFavism or thyroiditisCoagulopathiesNeurovegetative diseasesAngina                                                                                                                                                                                                                                                                                                                                                                 Secondary MortalityLOS hospitalLaboratory inflammatory markers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  NCT04342689[@b66-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Multicenter, randomized, blinded, phase 3                                                                                                                                                                                          Resistant starch 2 tbsp (\~ 20 g) PO daily × 3 d then PO BID through 14 d (n=750)                                                                                                                       Inclusion Age \> 18 yearsCOVID-positive statusMonitored in an outpatient setting at a study institution                                                                                                                                                                                                                                                                                           Not yet recruiting; 5/1/21              Primary Hospitalization for COVID-19 complication
  The role of resistant starch in COVID-19 infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Placebo starch 2 tbsp (\~ 20 g) PO daily × 3 d then PO BID through 14 d (n=750)                                                                                                                                                                                                                                                                            Exclusion IBDHistory of gastric bypass surgeryActive CDIActive participation in another COVID-19 interventional trialCondition that would pose unacceptable risk to the patient or raise concern for complianceStarch allergyDifficulty swallowingCurrently taking any IL-6 inhibitors                                                                                                                                                                                                                                                         Secondary Time to clinical recoverySymptom severity score                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  ***Vitamin A***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  IRCT20170117032004N3[@b67-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                   Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Two arm, parallel group randomized, controlled                                                                                                                                                                                     SC + vitamin A 50,000 IU daily × 2 wks (n=15)                                                                                                                                                           Inclusion \> 18 yoConfirmed diagnosis of COVID-19 with RT-PCRHospitalized, ventilator-independent patients                                                                                                                                                                                                                                                                                        Recruiting; 7/20/20                     Primary LOS hospitalization
  Evaluation of the effect of vitamin A on respiratory signs and hospitalization in patients with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  SC × 2 wks (n=15)                                                                                                                                                                                                                                                                                                                                          Exclusion Pregnant or lactatingHigh-dose vitamin A use in last mo                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Secondary Respiratory signs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  IRCT20180520039738N2[@b68-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                   Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Randomized, controlled, double-blinded                                                                                                                                                                                             SC + vitamin A 25,000 IU/d × 10 d (n=70)                                                                                                                                                                Inclusion 1--75 yoCOVID-19 diagnosis                                                                                                                                                                                                                                                                                                                                                              Recruitment complete; results pending   Primary Vital signsLaboratory inflammatory markers
  Comparison of the effectiveness of standard treatment with standard treatment plus vitamin A in treatment in COVID-19 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  SC + placebo (n=70)                                                                                                                                                                                                                                                                                                                                        Exclusion Pregnant or lactating womenAutoimmune diseases (lupus, MS, etc.)Hepatitis B or CUse of vitamin AChronic renal, liver, or heart failureCOPD                                                                                                                                                                                                                                                                                                                                                                                           Secondary None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  ***Vitamin B***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  DRKS00021214[@b70-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                           Germany                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Randomized, parallel group, blinded, placebo-controlled, single-center                                                                                                                                                             Nicotinamide 1000 mg (500 mg × 2 tablets) PO daily × 4 wks (n=650)                                                                                                                                      Inclusion \> 18 yoConfirmed SARS-CoV-2 infectionRespiratory symptoms                                                                                                                                                                                                                                                                                                                              Recruitment planned; not provided       Primary Hospitalization w/continuous O2 requirement \> 24 hSecondary VentilationMortalityER visitsICU staysResolution of symptomsSeverity improvement
  Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease (COVit)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Placebo silica 245 mg PO daily × 4 wks (n=650)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  ***Vitamin C***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  NCT04264533[@b71-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Randomized, parallel-assignment, blinded, placebo-controlled, single-center                                                                                                                                                        Vitamin C 12 g IV BID × 7 d (infusion rate 12 mL/hr) (n=70)                                                                                                                                             Inclusion \> 18 yoDiagnosed with serious or critical COVID-19Receiving treatment in ICU                                                                                                                                                                                                                                                                                                           Recruiting; 9/30/20                     Primary Ventilator-free d
  Vitamin C Infusion for the treatment of severe 2019-nCoV infected pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Placebo sterile water 50 mL IV BID × 7 d (infusion rate 12 mL/hr) (n=70)                                                                                                                                                                                                                                                                                   Exclusion Vitamin C allergyDyspnea due to cardiogenic pulmonary edemaPregnant or breastfeedingLife expectancy \<24 hTracheotomy or home O2 therapy requirementPreviously complicated with end-stage lung disease, end-stage malignancy, G6PD, diabetic ketoacidosis, and active kidney stone diseaseSimultaneous participation in another clinical trial                                                                                                                                                                                       Secondary 28-d mortalityLOS ICUNeed for CPRVasopressor daysVentilator parametersAPACHE II and SOFA scores                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  NCT04323514[@b72-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Italy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Open label, longitudinal                                                                                                                                                                                                           Vitamin C 10 g IV + SC (n=500)                                                                                                                                                                          Inclusion In case of doubt of interstitial pneumonia with indications for intubationPositive swab test of SARS-CoV-2Interstitial pneumonia                                                                                                                                                                                                                                                        Recruiting; 3/13/21                     Primary In-hospital mortality
  Use of ascorbic acid in patients with COVID 19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Exclusion Negative swab for SARS-CoV-2                                                                                                                                                                                                                                                                                                                     Secondary PCR levelsLactateLOS hospitalSymptoms and resolution of symptoms (fever, cough, shortness of breath, or difficulty breathing)Positive COVID-19 swabDuration of positive COVID-19 swabTomography imaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NCT04344184[@b73-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Phase II, randomized, blinded, placebo-controlled                                                                                                                                                                                  L-ascorbic acid 100 mg/kg IV q8 hrs × 72 hrs max (n=100)                                                                                                                                                Inclusion \>18 yoHospitalized patients diagnosed with COVID-19 based on positive RT-PCR with hypoxemiaNew SpO2 \<93% on room air or new requirement of supplemental O2Any increase in requirement of supplemental O2 in patients requiring home O2                                                                                                                                                Not yet recruiting; May 2021            Primary Number of ventilator-free days
  Early infusion of vitamin C for treatment of novel coronavirus acute lung injury (EVICT-CORONA-ALI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Placebo dextrose 5% water IV (n=100)                                                                                                                                                                                                                                                                                                                       Exclusion Vitamin C allergyPresence of diabetic ketoacidosisActive kidney stonesPregnantIncarcerated                                                                                                                                                                                                                                                                                                                                                                                                                                           Secondary All-cause-mortalityAcute inflammation-free daysOrgan-failure-free days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  NCT04357782[@b74-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Single-center, open-label                                                                                                                                                                                                          L-ascorbic acid 50 mg/kg IV q6 hrs × 4 d (16 doses) (n=20)                                                                                                                                              Inclusion 18--99 yoHospitalized patients diagnosed with COVID-19 based on positive RT-PCRMild deoxygenation S/F ratio decreased by 25% from baseline on admission, or SpO2 \<95% on room airNon-childbearing potential or childbearing potential with a negative pregnancy test at screening, and using a reliable method of contraception                                                        Recruiting; 8/1/20                      Primary Incidence of adverse eventsIncidence of serious adverse eventsIncidence of adverse reactions
  Administration of intravenous vitamin C in novel coronavirus infection and decreased oxygenation (AVoCaDO): A phase I/II safety, tolerability, and efficacy clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Exclusion Vitamin C allergyStage IV or above CKDPresence of diabetic ketoacidosis, use of insulin infusion, or frequent need for point-of-care glucose monitoring (\>6 times/24 hr period) as determined by treating physicianG6PD deficiencyKidney stone historyPregnancyEnrolled in another COVID-19 trial that does not allow concomitant study drugs   Secondary Ventilator-free daysICU-free daysHospital-free daysAll-cause mortalityChange in SpO2/FiO2 ratio during HDVIC infusionChange in CRP, LDH, D-dimer, lymphocyte count, NLR, serum ferritin from baseline to d 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  NCT04363216[@b75-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  single-center, prospective, randomized, open-label, phase II clinical trial                                                                                                                                                        Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) 1 g/L sterile water (+ 1 g/L magnesium chloride to reduce burning sensation) IV over 2 hrs at doses below q 24 hrs (+4) × 5 days (n=66)   Inclusion Male or non-pregnant female\> 18 yoConfirmed SARS-CoV-2 infectionDisease severity necessitating hospitalizationCurrently taking supplemental O2No anticipated need (within 24 hrs) for mechanical ventilation, defined as: (1) positive clinical response to O2 supplementation w/improvement in hypoxia or (2) hypoxia improvement with bronchospasm therapy if bronchospasm present   Not yet recruiting; May 2021            Primary Clinical improvement
  Pharmacologic ascorbic acid as an activator of lymphocyte signaling for COVID-19 treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  D 0 (enrollment day)- 0.3 g/kg; D 1- 0.6 g/kg; D 2- 0.9 g/kg; D 3- 0.9 g/kg; D 4- 0.9 g/kg; D 5- 0.9 g/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  SC (n=22)                                                                                                                                                                                                                                                                                                                                                  Exclusion eGFR \< 50G6PD deficiencyAnticipated need for mechanical ventilation within 24 hrsPregnant or breastfeedingRequires home O2 for any reason                                                                                                                                                                                                                                                                                                                                                                                           Secondary Patient care escalated to ICUO2 supplementationDays with feverDays to dischargeSerious AE related to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  ChiCTR2000032400[@b76-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                       China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Prospective, randomized, controlled, cohort                                                                                                                                                                                        High dose IV Vitamin C 100 mg/kg/d (n=60)                                                                                                                                                               Inclusion Fever, respiratory tract and other symptomsImaging consistent with pneumonia                                                                                                                                                                                                                                                                                                            Recruiting; 6/1/20                      Primary CRP, ESRSIRS
  The efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): A prospective, randomize, controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Placebo normal saline (n=60)                                                                                                                                                                                                                                                                                                                               Exclusion \< 18 yoTreatment for tumorPregnant or lactatingKnown kidney stone(s)Vitamin C allergyOther clinical trial involvement                                                                                                                                                                                                                                                                                                                                                                                                               Secondary CD4+ lymphocyte count, lymphocyte count, PaO2/FiO2 indicator, total bilirubin, cTNI, APPT, D-dimer, LDH, CK, ratio of turning to severe virus, and crystalluria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  ***Vitamin D***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  NCT04334005[@b79-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Spain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Randomized, parallel assignment, double-blind                                                                                                                                                                                      Vitamin D 25,000 IU PO daily (in AM w/toast + olive oil to facilitate absorption) + NSAIDs, ACE2 inhibitor, ARB, or TZDs based on investigator (n=100)                                                  Inclusion 40--70 yoNon-severe symptomatic patients presenting with cough, fever, nasal congestion, GI symptoms, fatigue, anosmia, ageusia, or alternative signs of respiratory infections                                                                                                                                                                                                         Not yet recruiting; 6/30/20             Primary Composite of cumulative death for all causes and specific causes
  Effect of vitamin D administration on prevention and treatment of mild forms of suspected COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Usual care (NSAIDs, ACE2 inhibitor, ARB, or TZDs based on investigator) (n=100)                                                                                                                                                                                                                                                                            Exclusion Severe respiratory and/or multisystemic symptoms suggesting advanced COVID-19 and intercurrent acute or severe chronic diseases (cancers)                                                                                                                                                                                                                                                                                                                                                                                            Secondary Need for (non)invasive ventilationICU or PACU or hospital admissionMedical consultationHome care and isolation timeBedrest timeDuration of symptoms and recovery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  NCT04344041[@b80-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            France                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Multicenter, randomized, parallel assignment                                                                                                                                                                                       High dose vitamin D 400,000 IU PO daily (n=130)                                                                                                                                                         Inclusion ≥ 70 yoDiagnosis of COVID-19 by RT-PCR SARS-CoV-2 or CT scan suggesting viral pneumoniaDiagnosed within the preceding 3 dAt least 2 risk factors for complications: (1) ≥ 75 yo, (2) SpO2 ≤ 94% on room air or a PaO2 to FiO2 ratio ≤ 300 mmHgSocial security recipient                                                                                                                 Recruiting; July 2020                   Primary Number of deaths from any cause during the 14 d following the inclusion and intervention
  COVID-19 and vitamin D supplementation: a multicenter randomized controlled trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients (CoVitTrial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Standard dose vitamin D 50,000 IU PO daily (n=130)                                                                                                                                                                                                                                                                                                         Exclusion Organ failure requiring admission to a resuscitation or high dependency unitLife-threatening comorbidity with short-term life expectancy (\<3 mos life)Any reason that makes follow-up at D 28 impossibleVitamin D supplementation in the previous mo (exception of \< 800 IU of vitamin D/d)Contraindication for vitamin D supplementationParticipation in another simultaneous trialPersons deprived of liberty, under psychiatric care under duress, subject to legal protectionSpO2 ≤ 92% in spite of an O2 therapy \> 5 L/min   Secondary Overall and by 25-OHD level at defined time pointsMortalityChange in WHO OSCI for COVID-19 Severe AE14-d mortality, compared to French hospital geriatric units                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  NCT04363840[@b81-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Phase II, multicenter, prospective, randomized, controlled                                                                                                                                                                         Aspirin 81 mg PO daily × 14 d (n=360)                                                                                                                                                                   Inclusion \> 18 yoCOVID-19 diagnosis in the past 24 h                                                                                                                                                                                                                                                                                                                                             Not yet recruiting; 12/2020             Primary Hospitalization
  The LEAD COVID-19 trial: low-risk, early aspirin and vitamin D to reduce COVID-19 hospitalizations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Aspirin 81 mg PO daily + vitamin D 50,000 IU PO daily × 14 d (n=360)                                                                                                                                                                                                                                                                                       Exclusion Pregnant patientsPrisonersHistory of GI bleed, PUD, spontaneous bleeds, thrombocytopenia, CKDConcurrent NSAID or steroid useHypervitaminosis D and associated risk factors (renal failure, liver failure, hyperparathyroidism, sarcoidosis, histoplasmosis)                                                                                                                                                                                                                                                                          Secondary None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  No intervention (n=360)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  NCT04366908[@b82-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Spain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Randomized, open-label, parallel assignment                                                                                                                                                                                        Best available therapy (BAT) + calcifediol 266 mcg × 2 capsules PO once on D 1 then × 1 capsule on D 3, 7, 14, 21, and 28 (n=504)                                                                       Inclusion 18--90 yoPCR confirmed diagnosis of COVID-19Radiological image with inflammatory pleuropulmonary exudate                                                                                                                                                                                                                                                                                Not yet recruiting; 8/28/20             Primary Admission to ICUDeath
  Prevention and treatment with calcifediol of COVID-19 coronavirus-induced acute respiratory syndrome (SARS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  BAT combination therapy as defined by the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (n=504)                                                                                                                                                                                              Exclusion Treatment with calcifediol or cholecalciferolIntolerance or allergy to calcifediol or its componentsPregnancy                                                                                                                                                                                                                                                                                                                                                                                                                        Secondary Time to dischargeICU: time to admission, time mechanical ventilation is removedLaboratory inflammatory markersVitamin D metabolitesSpO2 and SatO2/FiO2DyspneaRadiologic findingsAEsHemorrhagic or thrombotic phenomena                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  ***Multiple agents studied***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  NCT04334512[@b77-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Phase II, randomized, double-blind, placebo-controlled                                                                                                                                                                             Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, + Zinc × 10 d (n=300)                                                                                                                           Inclusion 18--55 yo\> 2 highly effective birth control methodDiagnosis of COVID-19 by RT-PCR                                                                                                                                                                                                                                                                                                      Not yet recruiting; 4/2021              Primary Successful treatment: negative test and resolution of symptomsSafety Tolerability
  A study of quintuple therapy to treat COVID-19 infection (HAZDpaC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Matching placebo (n=300)                                                                                                                                                                                                                                                                                                                                   Exclusion Screening test negative for COVID-19 by RT-PCRDiarrhea (prior to infection)Any comorbidities the investigator constitutes a health risk for the subject                                                                                                                                                                                                                                                                                                                                                                              Secondary None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  NCT04342728[@b78-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Randomized, single-center, prospective, open label four arm                                                                                                                                                                        Vitamin C 8000 mg PO divided into 2--3 doses/d w/food (n=130)                                                                                                                                           Inclusion \>18 yoOutpatientPositive test for COVID-19Non-pregnant                                                                                                                                                                                                                                                                                                                                 Enrolling by invitation; 4/30/21        Primary Symptom reduction
  Coronavirus disease 2019- using ascorbic acid and zinc supplementation (COVIDAtoZ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Zinc gluconate 50 mg PO at bedtime (n=130)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Vitamin C + Zinc gluconate (dosing as above) (n=130)                                                                                                                                                                                                                                                                                                       Exclusion Positive for COVID-19 in hospital or ERPatients living outside of OhioPregnant or lactatingEnd-stage CKDAdvanced liver disease awaiting transplantationHistory of kidney stones                                                                                                                                                                                                                                                                                                                                                      Secondary Resolution of fever, cough, shortness of breath, and fatigueSymptoms at D 5HospitalizationsSeverity of symptomsAdjunctive medicationsAEs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  SC (n=130)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  NCT04351490[@b83-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            France                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Randomized, parallel assignment, open label                                                                                                                                                                                        Zinc gluconate capsule 15 mg × 2/d + 25-OH cholecalciferol drinkable solution 10 drops (2000 IU)/d × 2 mos (n=1570)                                                                                     Inclusion \> 60 yoHospitalized                                                                                                                                                                                                                                                                                                                                                                    Not yet recruiting; July 2020           Primary Survival rate in asymptomatic subjects
  Impact of zinc and vitamin D3 supplementation on the survival of institutionalized aged patients infected with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  SC (n=1570)                                                                                                                                                                                                                                                                                                                                                Exclusion Life expectancy \< 1 mo independent of COVID-19 infectionHypercalcemiaRenal lithiasis                                                                                                                                                                                                                                                                                                                                                                                                                                                Secondary Survival rateCOVID-19 incidence in asymptomatic subjects at inclusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  NCT04370288[@b62-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                            Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Phase I, randomized, parallel assignment, single center                                                                                                                                                                            MCN (Methylene blue, vitamin C, N-acetyl cysteine) (n=10)                                                                                                                                               Inclusion 18--90 yoConfirmed case of COVID-19 (by RT-PCR, HRCT)Admission to ICUNeed for intubation and mechanical ventilation (PaO2/FiO2 \< 100--200)                                                                                                                                                                                                                                             Recruiting; 9/20/20                     Primary Free from mechanical ventilation in both groups
  The clinical trial of application of methylene blue vial for treatment of COVID-19 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  SC (n=10)                                                                                                                                                                                                                                                                                                                                                  Exclusion Pregnancy and breastfeedingG6PD deficiencyPreadmission anticoagulationRenal or hepatic diseaseAllergy to methylene blueImmunosuppressive agentsUse of other investigational drugs at inclusion                                                                                                                                                                                                                                                                                                                                       Secondary MortalityImprovement in Pa02/Fi02 ratioLOS hospitalLOS ICUDialysis-free daysCRPWBC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  IRCT20200319046819N1[@b69-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                   Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Randomized, single-blinded, parallel                                                                                                                                                                                               Vitamin A 25,000 IU PO daily + vitamin D 600,000 IU PO × 1 + vitamin E 300 IU PO BID + vitamin C 500 mg PO QID + vitamin B (Soluvit) 1 ampule daily × 1 wk (n=30)                                       Inclusion: 20--60 yoCOVID-19 clinical or definitive diagnosisBMI 18.5--30No liver or kidney disorders                                                                                                                                                                                                                                                                                             Recruiting; not provided                Primary Inflammatory makersPulmonary involvement (CT)Mortality
  Impact of vitamin B, A, D, E, and C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  SC (n=30)                                                                                                                                                                                                                                                                                                                                                  Exclusion: Rare viral diseasesChemotherapy in prior moAny other specific condition                                                                                                                                                                                                                                                                                                                                                                                                                                                             Secondary BMILOSSpO2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  IRCT20200324046850N1[@b63-dic-2020-5-7]\                                                                                                                                                                                                                                                                                                                   Iran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Randomized, single-blinded, factorial trial                                                                                                                                                                                        SC w/national drugs (n=25)                                                                                                                                                                              Inclusion COVID-19 positive based on chest CT with severe symptoms (fever, muscle pain, SOB, dry cough, sore throat, runny nose)Confirmation of COVID-19 by an infectious disease physician                                                                                                                                                                                                       Recruiting; 5/21/20                     Primary SOB, cough, chills, night sweats
  Comparison of vitamin D3 and N-acetylcysteine prescription in COVID-19 patients and their effect on recovery process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  SC w/national drugs + vitamin D3 50,000 IU once a wk (n=25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  SC w/national drugs + n-acetylcysteine (NAC) 600 mg PO daily (n=25)                                                                                                                                                                                                                                                                                        Exclusion Taking medications other than the ones mentioned in this studyPregnant and lactating womenTaking losartan or captoprilHistory of intestinal ulcers or GI bleed                                                                                                                                                                                                                                                                                                                                                                       Secondary None reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  SC w/national drugs + vitamin D3 50,000 IU + NAC 600 mg PO once a wk (n=25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

25-OHD, calcifediol; ACE2, Angiotensin-converting enzyme 2; AE, adverse event; AM, morning; APACHE, Acute Physiologic Assessment and Chronic Health Evaluation; APPT, activated partial thromboplastin time; ARB, Angiotensin II receptor blockers; BID, twice daily; BMI, body mass index; CDI: *Clostridium difficile* infection; CK, creatine kinase; CKD, chronic kidney disease; cm, centimeter; COPD, chronic obstructive pulmonary disorder; CPR, cardiopulmonary resuscitation; CRP, c-reactive protein; CT, computerized tomography; cTNI, cardiac troponin I; d, day; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; ER, emergency room; ESR, erythrocyte sedimentation rate; g, gram; G6PD, glucose-6-phosphate dehydrogenase; GI, gastrointestinal; GLA, gamma-linolenic acid; HDVIC, high dose IV vitamin C; HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; hr(s), hour(s); IBD, inflammatory bowel disease; ICU, intensive care unit; IL-6, interleukin-6; IU, international unit; IV, intravenous; kg, kilogram; L, liter; LDH, lactate dehydrogenase; LOS, length of stay; LPV/r, lopinavir/ritonavir; mcg, microgram; mg, milligram; mL, milliliter; mmHg, millimeter of mercury; mo(s), month(s); MS, multiple sclerosis; n= number; NEWS, national early warning score; NLR, neutrophil-lymphocyte ratio; NGT, nasogastric tube; NPO, nil per os; NSAID(s), Nonsteroidal anti-inflammatory drugs; O2, oxygen; ONS, oral nutritional supplements; OSCI, Ordinal Scale for Clinical Improvement (0 to 8; higher score, poorer outcome); PACU, post-anesthesia care unit; PaO2/FiO2, partial pressure of oxygen/fraction of inspired oxygen;, PN, parenteral nutrition; PO, oral; PUD, peptic ulcer disease; QID, four times daily; RT-PCR, reverse transcriptase polymerase chain reaction; SIRS, Systemic inflammatory response syndrome; SOB, shortness of breath; SOFA, sequential organ failure estimate; SC, standard of care; SpO2, oxygen saturation; SpO2/FiO2, oxygen saturation/fraction of inspired oxygen; tbsp, tablespoon; TID, three times daily; TZDs, thiazolidinediones; w/, with; WBC, white blood cell; w/o, without; y, yo (age).
